Posts by: Alejandra Viviescas, PhD

Alejandra Viviescas, PhD

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.

December 11, 2019

Cancer Research Teams Working to Identify Early Biomarkers of Ovarian Cancer

News

With a $544,360 developmental grant from the U.S. Department of Defense (DoD), four research teams are joining efforts to identify biomarkers of ovarian cancer with a goal of detecting the ... Read more

November 6, 2019

Syros’ SY-5609 Shows Promising Activity in OC Models, Supports Planned Phase 1 Trial, Results Show

News

Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The findings ... Read more

September 25, 2019

Spherix Acquires Rights to Anthrax Toxin Altered to Target Ovarian Cancer

News

Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore (UMB). ... Read more

September 18, 2019

IMV, Wistar Institute Partner to Develop T-cell Immunotherapy Against Cancers with BRAF Mutations

News

IMV announced that it has joined with the Wistar Institute to develop an immunotherapy targeting cancer cells with mutations in the BRAF gene. Such mutations are linked to some types of ... Read more

August 16, 2019

Immix Cleared to Expand Phase 1/2a Trial of IMX-110 to US Sites

News

A Phase 1/2a trial testing the advanced solid tumor treatment candidate IMX-110 in Australia has been cleared by the U.S. Food and Drug Administration to enroll participants in the United ... Read more

August 14, 2019

Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC

News

Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The open-label ... Read more

August 9, 2019September 10, 2019

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

News

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking ... Read more

June 14, 2019June 14, 2019

First Patient Dosed in Phase 2 Trial Evaluating Ampligen-Keytruda-Chemo Combo for Ovarian Cancer

News

The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial (NCT03734692) is ... Read more

June 3, 2019

OncBioMune’s Experimental Chemo Shows Potential to Inhibit Growth of Drug-resistant OC Cells

News

PGT, an experimental chemotherapy developed by OncBioMune, inhibited the growth of ovarian cancer cells resistant to multiple chemotherapeutic agents. These preliminary results suggest that the therapy could potentially be used ... Read more